Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Bayer AM, Danysh HE, Garvich M, Gonzalvez G, Checkley W, Alvarez M, Gilman RH. An unforgettable event: a qualitative study of the 1997-98 El Niño in northern Peru. Disasters. 2014 Apr;38(2):351-74. doi: 10.1111/disa.12046
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Goyal RK, Patel JG, Sansgiry SS. Pharmacists perceptions of drug reimbursement rates and processing times among managed care plans. Drug benefit trends: a publication for manager and health professionals in hmos and ppos. 2010;22(4):116-20.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
Mansfield CA. A consistent method for calibrating contingent value survey data. South Econ J. 1998;64(3):665-81.